Profile data is unavailable for this security.
About the company
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.
- Revenue in USD (TTM)0.00
- Net income in USD-44.60m
- Incorporated2013
- Employees19.00
- LocationCorbus Pharmaceuticals Holdings Inc500 River Ridge DriveNORWOOD 02062United StatesUSA
- Phone+1 (617) 963-0103
- Websitehttps://www.corbuspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics Inc | 50.58m | -7.87m | 346.76m | 135.00 | -- | -- | -- | 6.86 | -0.1437 | -0.1437 | 0.7691 | -1.55 | 0.8836 | 3.32 | 7.68 | 374,688.90 | -13.75 | -76.63 | -27.78 | -123.85 | 58.82 | 64.24 | -15.56 | -102.95 | 1.87 | -- | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Precigen Inc | 6.23m | -95.90m | 350.98m | 202.00 | -- | 2.96 | -- | 56.38 | -0.3933 | -0.3933 | 0.0255 | 0.476 | 0.0339 | -- | 6.62 | 30,816.83 | -52.26 | -31.50 | -72.27 | -38.63 | 1.70 | 44.00 | -1,540.63 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Revance Therapeutics Inc | 234.04m | -323.99m | 354.33m | 534.00 | -- | -- | -- | 1.51 | -3.81 | -3.81 | 2.77 | -1.72 | 0.4414 | 2.33 | 12.00 | -- | -61.11 | -55.55 | -72.36 | -63.20 | 68.23 | -- | -138.43 | -304.96 | 3.29 | -36.36 | 1.54 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Mersana Therapeutics Inc | 36.86m | -171.67m | 356.63m | 123.00 | -- | 9.62 | -- | 9.68 | -1.50 | -1.50 | 0.3175 | 0.3057 | 0.1315 | -- | 2.46 | 299,634.20 | -61.27 | -61.68 | -84.73 | -81.35 | -- | -- | -465.80 | -622.19 | -- | -- | 0.408 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Aura Biosciences Inc | 0.00 | -76.41m | 357.42m | 88.00 | -- | 1.58 | -- | -- | -1.93 | -1.93 | 0.00 | 4.58 | 0.00 | -- | -- | 0.00 | -31.90 | -- | -33.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| ADC Therapeutics SA | 69.56m | -240.05m | 358.18m | 273.00 | -- | -- | -- | 5.15 | -2.94 | -2.94 | 0.8528 | -1.80 | 0.1645 | 0.179 | 1.42 | 254,791.20 | -55.47 | -48.41 | -67.39 | -55.63 | 96.36 | -- | -337.16 | -308.62 | 4.73 | -4.70 | 1.55 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Amarin Corporation plc (ADR) | 306.91m | -59.11m | 359.30m | 275.00 | -- | 0.6479 | -- | 1.17 | -0.145 | -0.145 | 0.7529 | 1.35 | 0.3573 | 0.4192 | 2.32 | 1,116,040.00 | -6.88 | -4.48 | -9.86 | -6.54 | 66.72 | 75.70 | -19.26 | -8.59 | 1.80 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Esperion Therapeutics Inc | 116.33m | -209.25m | 359.86m | 240.00 | -- | -- | -- | 3.09 | -2.11 | -2.11 | 1.13 | -3.85 | 0.5128 | 0.8583 | 2.83 | 484,725.00 | -92.23 | -69.45 | -203.94 | -101.81 | 62.81 | -- | -179.87 | -147.44 | 0.867 | -2.85 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -44.60m | 359.87m | 19.00 | -- | -- | -- | -- | -10.38 | -10.38 | 0.00 | -1.56 | 0.00 | -- | -- | 0.00 | -94.31 | -86.84 | -178.23 | -130.46 | -- | -- | -- | -769.76 | -- | -15.46 | 1.74 | -- | -- | -- | -5.33 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -37.64m | 364.82m | 11.00 | -- | -- | -- | -- | -5.69 | -5.69 | 0.00 | -0.1726 | 0.00 | -- | -- | 0.00 | -357.65 | -232.67 | -- | -- | -- | -- | -- | -- | -- | -43.27 | 1.95 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Nature's Sunshine Products Inc | 445.32m | 15.08m | 366.97m | 814.00 | 25.28 | 2.39 | 13.00 | 0.8241 | 0.7715 | 0.7715 | 22.78 | 8.16 | 1.86 | 1.84 | 38.84 | 547,076.20 | 6.85 | 6.57 | 10.02 | 9.41 | 72.11 | 72.69 | 3.69 | 3.74 | 1.29 | -- | 0.00 | 27.72 | 5.55 | 4.07 | 3,965.64 | -- | 16.73 | -- |
| Medifast Inc | 1.07bn | 99.41m | 367.29m | 634.00 | 3.70 | 1.82 | 3.26 | 0.3426 | 9.11 | 9.11 | 98.22 | 18.49 | 3.42 | 3.42 | 245.69 | 1,690,939.00 | 31.76 | 41.25 | 50.60 | 69.38 | 72.37 | 73.20 | 9.27 | 10.06 | 1.84 | -- | 0.00 | 49.18 | -32.94 | 16.43 | -30.75 | 12.25 | 5.59 | 17.72 |
| Tscan Therapeutics Inc | 21.05m | -89.22m | 368.21m | 154.00 | -- | 2.32 | -- | 17.49 | -2.49 | -2.49 | 0.4421 | 3.15 | 0.0893 | -- | -- | 136,681.80 | -37.87 | -- | -42.07 | -- | -- | -- | -423.86 | -- | -- | -- | 0.1661 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Heron Therapeutics Inc | 127.04m | -110.56m | 368.31m | 126.00 | -- | -- | -- | 2.90 | -0.8695 | -0.8695 | 0.9494 | -0.2261 | 0.5367 | 1.35 | 2.26 | 1,008,286.00 | -46.70 | -53.55 | -71.00 | -71.24 | 48.75 | 52.52 | -87.02 | -170.12 | 1.84 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Harrow Inc | 130.19m | -24.41m | 372.37m | 315.00 | -- | 5.23 | -- | 2.86 | -0.7448 | -0.7448 | 3.99 | 2.01 | 0.5546 | 4.55 | 6.13 | 413,311.10 | -10.40 | -10.86 | -12.14 | -12.71 | 69.55 | 70.75 | -18.75 | -15.35 | 2.61 | 0.0445 | 0.7223 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Cartesian Therapeutics Inc | 26.00m | -219.71m | 373.91m | 38.00 | -- | -- | -- | 14.38 | -41.77 | -41.77 | 5.03 | -25.87 | 0.1104 | -- | 4.17 | 684,315.80 | -93.31 | -43.66 | -116.36 | -66.84 | -- | -- | -844.91 | -136.35 | -- | -0.5814 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
Data as of Apr 26 2024. Currency figures normalised to Corbus Pharmaceuticals Holdings Inc's reporting currency: US Dollar USD
53.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cormorant Asset Management LPas of 22 Mar 2024 | 2.03m | 19.30% |
| Adage Capital Management LPas of 22 Mar 2024 | 796.39k | 7.59% |
| Millennium Management LLCas of 22 Mar 2024 | 544.28k | 5.19% |
| RA Capital Management LPas of 02 Feb 2024 | 430.18k | 4.10% |
| Tang Capital Management LLCas of 26 Jan 2024 | 426.22k | 4.06% |
| Paradigm BioCapital Advisors LPas of 26 Jan 2024 | 399.66k | 3.81% |
| Point72 Asset Management LPas of 26 Jan 2024 | 388.68k | 3.70% |
| Assenagon Asset Management SA (Germany)as of 31 Mar 2024 | 259.46k | 2.47% |
| Ikarian Capital LLCas of 31 Dec 2023 | 195.90k | 1.87% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 177.85k | 1.70% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
